Similar articles

• Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

  Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Caprilli R, et al. Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
• Are we ready for top-down therapy for inflammatory bowel diseases: pro.

  van der Woude CJ, Hommes DW. van der Woude CJ, et al. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):243-8. doi: 10.1586/17474124.1.2.243. Expert Rev Gastroenterol Hepatol. 2007. PMID: 19072416 Review.
• Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.

  Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Passarini B, et al. Dermatology. 2007;215(4):295-300. doi: 10.1159/000107622. Dermatology. 2007. PMID: 17911986
• The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.

  Kwon JH, Farrell RJ. Kwon JH, et al. Crit Rev Oncol Hematol. 2005 Oct;56(1):169-78. doi: 10.1016/j.critrevonc.2005.02.004. Crit Rev Oncol Hematol. 2005. PMID: 15979323 Review.
• Understanding the delayed onset of action of azathioprine in IBD: are we there yet?

  Atreya I, Neurath MF. Atreya I, et al. Gut. 2009 Mar;58(3):325-6. doi: 10.1136/gut.2008.163485. Gut. 2009. PMID: 19211850 No abstract available.